BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34527317)

  • 1. CHMP4C regulates lung squamous carcinogenesis and progression through cell cycle pathway.
    Liu B; Guo S; Li GH; Liu Y; Liu XZ; Yue JB; Guo HY
    J Thorac Dis; 2021 Aug; 13(8):4762-4774. PubMed ID: 34527317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSMA1, a Poor Prognostic Factor, Promotes Tumor Growth in Lung Squamous Cell Carcinoma.
    Liu Z; Wang W; Zhou Y; Li L; Zhou W
    Dis Markers; 2023; 2023():5386635. PubMed ID: 36776923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA damage repair gene signature model for predicting prognosis and chemotherapy outcomes in lung squamous cell carcinoma.
    Wang X; Huang Z; Li L; Wang G; Dong L; Li Q; Yuan J; Li Y
    BMC Cancer; 2022 Aug; 22(1):866. PubMed ID: 35941578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and Validation of Prognostic Regulation Network Based on RNA-Binding Protein Genes in Lung Squamous Cell Carcinoma.
    Zhao S; Liu Q; Li J; Hu C; Cao F; Ma W; Gao J
    DNA Cell Biol; 2021 Dec; 40(12):1563-1583. PubMed ID: 34931870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of key genes associated with progression and prognosis for lung squamous cell carcinoma.
    Ma X; Ren H; Peng R; Li Y; Ming L
    PeerJ; 2020; 8():e9086. PubMed ID: 32411535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic analysis identifies three-lncRNA signature as a potentially prognostic biomarker for lung squamous cell carcinoma using bioinformatics strategy.
    Hu J; Xu L; Shou T; Chen Q
    Transl Lung Cancer Res; 2019 Oct; 8(5):614-635. PubMed ID: 31737498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Combined RNA Signature Predicts Recurrence Risk of Stage I-IIIA Lung Squamous Cell Carcinoma.
    Sun L; Li J; Li X; Yang X; Zhang S; Wang X; Wang N; Xu K; Jiang X; Zhang Y
    Front Genet; 2021; 12():676464. PubMed ID: 34194476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new risk model for CSTA, FAM83A, and MYCT1 predicts poor prognosis and is related to immune infiltration in lung squamous cell carcinoma.
    Ding Y; Bian TT; Li QY; He JR; Guo Q; Wu CY; Chen SS
    Am J Transl Res; 2022; 14(11):7705-7725. PubMed ID: 36505278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of lncRNA biomarkers in lung squamous cell carcinoma using comprehensive analysis of lncRNA mediated ceRNA network.
    Li R; Yang YE; Jin J; Zhang MY; Liu X; Liu XX; Yin YH; Qu YQ
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3246-3258. PubMed ID: 31364871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Systematic Analysis of Dysregulated Long Non-Coding RNAs/microRNAs/mRNAs in Lung Squamous Cell Carcinoma.
    Zhang TJ; Cao JS; Li Q; An GS; Ni JH; Jia HT; Li SY
    Am J Med Sci; 2020 Dec; 360(6):701-710. PubMed ID: 33012486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Pyroptosis-Related Gene Signature for Early-Stage Lung Squamous Cell Carcinoma.
    Li X; He J
    Int J Gen Med; 2021; 14():6439-6453. PubMed ID: 34675612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients.
    Yan D; Chen Y
    Sci Rep; 2021 Apr; 11(1):9020. PubMed ID: 33907270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the Role and Regulation Mechanism of hsa-miR-147b in Lung Squamous Cell Carcinoma Based on The Cancer Genome Atlas Database.
    Ke D; Guo Q; Fan TY; Xiao X
    Cancer Biother Radiopharm; 2021 Apr; 36(3):280-291. PubMed ID: 33112657
    [No Abstract]   [Full Text] [Related]  

  • 14. LINC00628 is differentially expressed between lung adenocarcinoma and squamous cell carcinoma and is associated with the prognosis of NSCLC.
    Liu T; Xu S; Liu X
    Oncol Lett; 2022 Feb; 23(2):55. PubMed ID: 34992687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Survival-Associated Alternative Splicing Signatures in Lung Squamous Cell Carcinoma.
    Liu Y; Jia W; Li J; Zhu H; Yu J
    Front Oncol; 2020; 10():587343. PubMed ID: 33117720
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification and validation of an individualized prognostic signature of lung squamous cell carcinoma based on ferroptosis-related genes.
    Diao X; Guo C; Liu L; Wang G; Li S
    Thorac Cancer; 2021 Dec; 12(23):3236-3247. PubMed ID: 34672420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a seven-miRNA signature as prognostic biomarker for lung squamous cell carcinoma.
    Gao X; Wu Y; Yu W; Li H
    Oncotarget; 2016 Dec; 7(49):81670-81679. PubMed ID: 27835574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The necroptosis signature and molecular mechanism of lung squamous cell carcinoma.
    Song GQ; Wu HM; Ji KJ; He TL; Duan YM; Zhang JW; Hu GQ
    Aging (Albany NY); 2023 Nov; 15(22):12907-12926. PubMed ID: 37976123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the Lung Squamous Cell Carcinoma Diagnosis and Prognosis Markers by Unique DNA Methylation and Gene Expression Profiles.
    Wang W; Wang S; Chu X; Liu H; Xiang M
    J Comput Biol; 2020 Jul; 27(7):1041-1054. PubMed ID: 31710242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GABRP is a Promising Prognostic Biomarker and Associated with Immune Cell Infiltration in Lung Squamous Cell Carcinoma.
    Fu J; Lin J; Zeng X; Li G; Wei Y; Xian L
    Pharmgenomics Pers Med; 2023; 16():357-371. PubMed ID: 37091829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.